Eli Lilly's Foundayo Prescriptions Surge Post Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: seekingalpha
- Prescription Surge: Eli Lilly's new weight loss pill, Foundayo, saw prescriptions reach 1,390 for the week ending April 10, indicating a strong market response since its launch earlier this month, reflecting consumer acceptance of the new therapy.
- Competitor Performance: In contrast, Novo Nordisk's Wegovy approached 113,354 prescriptions during the same week, up from 105,366 the previous week, highlighting the sustained demand for GLP-1 drugs and intensifying competition in the market.
- FDA Approval Impact: Foundayo received FDA approval on April 1 as a once-daily treatment for obese or overweight adults, quickly accepting prescriptions through LillyDirect, showcasing the company's rapid market response capabilities.
- Market Outlook: With the launch of Foundayo, Eli Lilly significantly enhances its competitive position in the GLP-1 market, expected to challenge Novo Nordisk's market share and drive further growth in the overall weight loss drug market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.990
Low
950.00
Averages
1192
High
1500
Current: 903.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
Alphabet and Eli Lilly: Investment Opportunities for the Next Decade
- Diversified Growth for Google: Google enhances its search capabilities through AI, driving ad sales, and is expected to continue growth in cloud computing and streaming over the next decade, solidifying its market leadership.
- Self-Driving Business Potential: Google's Waymo operates in several U.S. cities with level 4 autonomy, and as self-driving cars gain traction over the next decade, it could significantly boost the company's revenue.
- Eli Lilly's Dominance in Weight Loss: Eli Lilly has made significant breakthroughs in the weight loss market and may accelerate drug development through AI drug discovery, potentially adding billions in revenue if successful.
- Transforming Drug Development Cycles: By shortening drug development times with AI, Eli Lilly could alter the typical pharmaceutical cycle, enhancing its competitiveness and long-term prospects in the market.
See More
Alphabet and Eli Lilly Show Bright Prospects Ahead
- Significant Investment Returns: An investment of $50,000 in either Alphabet or Eli Lilly since 2006 has grown to over $1 million, demonstrating their exceptional performance over the past two decades, with potential to continue outperforming the market in the future.
- AI-Driven Growth: Alphabet enhances its search capabilities through artificial intelligence, boosting user engagement and ad sales, and is expected to benefit from diversified businesses like cloud computing and YouTube over the next decade, solidifying its market leadership.
- Self-Driving Advantages: Alphabet's Waymo operates level 4 autonomous vehicles in several U.S. cities, and with partnerships like Uber and an established network, it is poised to capture significant market share in the self-driving car sector over the next ten years.
- Innovations in Drug Development: Eli Lilly's breakthroughs in the weight loss market and investments in AI drug discovery could significantly shorten drug development cycles, potentially generating billions in additional revenue and altering traditional pharmaceutical cycles.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Investment Opportunities in GLP-1 Drugs in Healthcare
- Eli Lilly's Market Performance: Eli Lilly reported a 45% sales increase in 2025, exceeding $65 billion, with net income nearing $21 billion, demonstrating its strong profitability in the GLP-1 drug market and solidifying its leadership in the healthcare sector.
- New Drug Approval Boosts Growth: The recent FDA approval of Eli Lilly's weight-loss drug Foundayo is expected to generate significant revenue, further enhancing its competitive edge in the rapidly growing healthcare market.
- Viking Therapeutics' Potential: Viking Therapeutics, with a market cap of only $4 billion, presents higher risk but shows promise with its GLP-1 drug VK2735 performing well in clinical trials; approval could attract large healthcare companies for acquisition, significantly increasing its market value.
- Balancing Risk and Reward: While Eli Lilly's stock is relatively safe, its price-to-earnings ratio exceeds 40, potentially limiting upside; in contrast, Viking Therapeutics could trigger a bidding war post-approval of VK2735, offering higher return potential.
See More
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
Alphabet and Eli Lilly: Investment Opportunities for the Next Decade
- Diversified Growth for Google: Google enhances its search capabilities through AI, driving ad sales, and is expected to continue growth in cloud computing and streaming over the next decade, solidifying its market leadership.
- Self-Driving Business Potential: Google's Waymo operates in several U.S. cities with level 4 autonomy, and as self-driving cars gain traction over the next decade, it could significantly boost the company's revenue.
- Eli Lilly's Dominance in Weight Loss: Eli Lilly has made significant breakthroughs in the weight loss market and may accelerate drug development through AI drug discovery, potentially adding billions in revenue if successful.
- Transforming Drug Development Cycles: By shortening drug development times with AI, Eli Lilly could alter the typical pharmaceutical cycle, enhancing its competitiveness and long-term prospects in the market.
See More
Alphabet and Eli Lilly Show Bright Prospects Ahead
- Significant Investment Returns: An investment of $50,000 in either Alphabet or Eli Lilly since 2006 has grown to over $1 million, demonstrating their exceptional performance over the past two decades, with potential to continue outperforming the market in the future.
- AI-Driven Growth: Alphabet enhances its search capabilities through artificial intelligence, boosting user engagement and ad sales, and is expected to benefit from diversified businesses like cloud computing and YouTube over the next decade, solidifying its market leadership.
- Self-Driving Advantages: Alphabet's Waymo operates level 4 autonomous vehicles in several U.S. cities, and with partnerships like Uber and an established network, it is poised to capture significant market share in the self-driving car sector over the next ten years.
- Innovations in Drug Development: Eli Lilly's breakthroughs in the weight loss market and investments in AI drug discovery could significantly shorten drug development cycles, potentially generating billions in additional revenue and altering traditional pharmaceutical cycles.
See More
Eli Lilly's GLP-1 Drug Sales Surge
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, indicating the company's leading position in the rapidly growing weight-loss market, which has driven its stock price up over 1,100% in the past decade.
- Valuation Risks: Despite Eli Lilly's P/E ratio of 39x, significantly above the industry average of 23x and close to its five-year average of 56x, a recent sell-off has made it relatively cheaper; however, the high absolute valuation may still deter potential investors.
- Patent Expiration Risks: With limited patent protection for Mounjaro and Zepbound, the emergence of generics could drastically reduce Eli Lilly's revenues from these GLP-1 drugs, posing a significant threat to its current dominance in the weight-loss category.
- Intensifying Competition: Eli Lilly faces fierce competition in the GLP-1 space from companies like Novo Nordisk and Pfizer, which are also developing similar drugs, potentially impacting Eli Lilly's market share and necessitating close monitoring of its ability to maintain its competitive edge.
See More
Eli Lilly's GLP-1 Drug Sales Surge Amid Competition
- Significant Sales Growth: Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, experienced sales increases of 99% and 175% respectively in 2025, indicating the company's strong position in the rapidly growing weight-loss market, despite fierce competition.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, yet potential risks must be acknowledged.
- Intensifying Competition Risks: With competitors like Novo Nordisk and Pfizer launching new drugs, Eli Lilly's dominance in the GLP-1 market may be threatened, particularly as patents expire and generics could significantly reduce its revenues.
- Acquisition Strategy Adjustment: Eli Lilly is leveraging the profits from its GLP-1 success to acquire companies in other areas, which may present new growth opportunities, but there is also the risk that the new drugs may not meet expectations, necessitating careful evaluation by investors.
See More
Investment Opportunities in GLP-1 Drugs in Healthcare
- Eli Lilly's Market Performance: Eli Lilly reported a 45% sales increase in 2025, exceeding $65 billion, with net income nearing $21 billion, demonstrating its strong profitability in the GLP-1 drug market and solidifying its leadership in the healthcare sector.
- New Drug Approval Boosts Growth: The recent FDA approval of Eli Lilly's weight-loss drug Foundayo is expected to generate significant revenue, further enhancing its competitive edge in the rapidly growing healthcare market.
- Viking Therapeutics' Potential: Viking Therapeutics, with a market cap of only $4 billion, presents higher risk but shows promise with its GLP-1 drug VK2735 performing well in clinical trials; approval could attract large healthcare companies for acquisition, significantly increasing its market value.
- Balancing Risk and Reward: While Eli Lilly's stock is relatively safe, its price-to-earnings ratio exceeds 40, potentially limiting upside; in contrast, Viking Therapeutics could trigger a bidding war post-approval of VK2735, offering higher return potential.
See More
